2019, Número 274
<< Anterior
16 de abril 2019; 58 (274)
Absceso tubo-ovárico en mujer portadora de dispositivo intrauterino hace 20 años
Larramendi BLC, Arzuaga LSS, Rosales RY, Ulloa CHA
Idioma: Español
Referencias bibliográficas: 20
Paginas: 139-142
Archivo PDF: 333.06 Kb.
RESUMEN
El absceso tubo-ovárico es una complicación de la enfermedad inflamatoria pélvica (EPI), caracterizado por la infección del tracto genital superior que se produce, casi siempre, por vía ascendente desde el cuello uterino. Se reportó de un caso de abdomen agudo causado por la rotura de un absceso tubo-ovárico bilateral en una mujer de 42 años portadora de un dispositivo intrauterino hace aproximadamente 20 años. Que consultó por cuadro de dolor abdominal, lumbar y fiebre. El diagnóstico se determinó mediante laparoscopia exploradora, se le realizó histerectomía abdominal total con doble anexectomía. La evolución postoperatoria fue satisfactoria.
REFERENCIAS (EN ESTE ARTÍCULO)
Joiner KA, Onderdonk AB, Gelfand JA, Bartlett JG, Gorbach SL. A quantitative model for subcutaneous abscess formation in mice. Brit J Exp Pathol. 1980; 61(1):97-107.
Stewar J. Ovarian abscess. Report of a case and a review of the literature. J Obst Gynecol Surg. 1985:40:476-485.
Hay PE y cols. Which sexually active young female students are most at risk of pelvic inflammatory disease? A prospective study. Sex. Transm Infect 2016; 92:63-6.
MINDY M. Ultrasound of Pelvic Inflammatory Disease. Ultrasound Quarterly 2004; 20: 171-9
Luedders DW, Chalvatzas N, Banz C, Horneman A, Diedrich K, KavallarisA.Tubo-ovarian abscess in woman with an intrauterine device forgotten for 22 years. Gynecol Surg. 2010;7: 181---4.
Soper DE. Pelvic Inflamatory Disease. Obstet Gynecol. 2010; 116:419---28.
Price MJ, Ades AE, De Angelis D y cols. Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model. Am J Epidemiol 2013; 178:484-92.
Sexually Transmited diseases treatment guidelines 2015. Centers for Disease Control and Prevention. MMWR Recomm Rep 2015; 51:1-78.
Oakeshott P, Aghaizu A, Hay P, et al. Is Mycoplasma genitalium in women the “New Chlamydia?” A community-based prospective cohort study. Clin Infect Dis 2010; 51:1160–6.
Hsu WC, Lee YH, Chang DY. Tuboovarian Abscess Caused by Candida in a Woman with an Intrauterine Device. Gynecol Obstet Invest. 2007; 64:14---6.
Charonis G, Larssson P-G. Prolonged use of intrauterine contraceptive device as a risk factor for tobo-ovarian abscess. Acta Obstetricia et Gynecologica. 2009; 88:680---4.
Grimes DA. Intrauterine device and upper genital tract infection. Lancet 2000; 356:1013.
Ross J y cols. 2012 European Guideline for the Management of Pelvic Inflammatory Disease. Int J STD AIDS. 2014; 25(1):1-7.
Workowski KA y cols. CDC. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015; 64(RR-03):1-137.
Thomassin-Naggara, E. Darai, M. Bazot. Gynecological pelvic infection: What is the role of imaging? 2015: 494
Sung Il Jung, Young Jun Kim, Hee Sun Park, Hae Jeong Jeon and Kyung-Ah Jeong2. Acute pelvic inflammatory disease: Diagnostic performance of CT J. Obstet. Gynaecol. Res. Vol. 37, No. 3: 228–235, March 2011.
Magrini L, Gagliano G, Travaglino F, Vetrone F, Marino R, Cardelli P, Salerno G, Di Somma S. Comparison between white blood cell count, procalcitonin and C reactive protein as diagnostic and prognostic biomarkers of infection or sepsis in patients presenting to emergency department. Clin Chem Lab Med. 2014 Oct; 52(10):1465-72. doi: 10.1515/cclm-2014-0210.
Tsai HT, Lee TH, Yang SF, Lin LY, Tee YT, Wang PH. Markedly elevated soluble E-cadherin in plasma of patient with pelvic inflammatory disease. Fertil Steril 2013; 99: 490-5
Brunham R y cols. Pelvic Inflammatory Disease. N Engl J Med 2015; 372: 2039-48.
Tepper NK, Steenland MW, Gaffield ME, Marchbanks PA, Curtis KM. Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review. Contraception 2013; 87: 655-60.